Treating viral hemorrhagic fever with nk-92 cells
AssigneeNantKwest, Inc.
InventorsTien Lee, Barry Simon
Life of this patent
Estimating the term…
Abstract
This disclosure is directed to treatment of a patient having or suspected of having viral hemorrhagic fever, comprising administering to the patient NK-92 cells.
Claims19
A method for treating viral hemorrhagic fever, the method comprising administering NK-92 cells to a patient who has or is suspected of having viral hemorrhagic fever.
A method for treating viral hemorrhagic fever in a patient who has or is suspected of having viral hemorrhagic fever, the method comprising administering to the patient NK-92 cells, wherein the viral hemorrhagic fever is caused by a virus that attacks cells expressing CD-16 receptor.
A method for treating a hemorrhagic disease in a patient in need thereof, comprising administering to the patient NK-92 cells, wherein the hemorrhagic disease is mediated by binding to a Fc receptor.
Dependencies are inferred from the claim text.